

Patrizia Cavazzoni
03/25/2002 08:52 PM

To: Lisa A Vierhile/AM/LLY@Lilly
cc: Jared G Kerr/AM/LLY@Lilly
Subject: Re: Japan update

Lisa

In Noriko's first e-mail, you will find documentation of "real-time" Lilly challenge of request for label change by MHLW, during the meeting with MHLW that occurred Moday 25 March (Japan time)

Patrizia

----- Forwarded by Patrizia Cavazzoni/AM/LLY on 03/25/2002 08:48 PM -----

Noriko Akagi
03/25/2002 07:11 PM

To: Anne Bille/AP/LLY@Lilly
cc: Akira Kokan/AP/LLY@Lilly, Andrew J Wood/AP/LLY@Lilly, Anna R Thornton/AP/LLY@Lilly, Anne Bille/AP/LLY@Lilly, Fumiko Sakakibara/AP/LLY@Lilly, Hiromasa Tara/AP/LLY@Lilly, James L Gahimer/AP/LLY@Lilly, Jared G Kerr/AM/LLY@Lilly, Keiichi Enomoto/AP/LLY@Lilly, Kenji Nobuhara/AP/LLY@Lilly, Koji Yamaguchi/AP/LLY@Lilly, Mark Lakshmanan/AP/LLY@Lilly, Mayumi Hagiwara/AP/LLY@Lilly, Michael L Zeckel/AM/LLY@Lilly, Mikihiro Kosuge/AP/LLY@Lilly, Namie Hara/AP/LLY@Lilly, Patrizia Cavazzoni/AM/LLY@Lilly, Rie Nagashiro/AP/LLY@Lilly, Sachiko Konaka/AP/LLY@Lilly, Takashi Taniguchi/AP/LLY@Lilly, Tetsu Kawade/AP/LLY@Lilly, Yasuko Kojima/AP/LLY@Lilly, Yasushi Ito/AP/LLY@Lilly, Yasutomo Senoo/AP/LLY@Lilly, Yukari Ohno/AP/LLY@Lilly, Yumi Kinoshita/AP/LLY@Lilly
Subject: Re: The result of the meeting with the MHLW today

Bille-san


A 'doctor letter' is NOT just a letters to doctors.

It is the most strict indication from the authorities. So we have to revise ZYP JP package insert to avoid the situation of distributing of the 'doctor letter'.

We will make a draft of the revision and sent it to you today, and discuss it tomorrow morning.

with regards,
Noriko Akagi

Anne Bille



Anne Bille
02/03/26 08:46

::: Noriko Akagi/AP/LLY@Lilly
cc: Andrew J Wood/AP/LLY@Lilly, Fumiko Sakakibara/AP/LLY@Lilly, Hiromasa Tara/AP/LLY@Lilly, Mark Lakshmanan/AP/LLY@Lilly, Anne Bille/AP/LLY, Akira Kokan/AP/LLY@Lilly, Noriko Akagi/AP/LLY@Lilly, Yasutomo Senoo/AP/LLY@Lilly, Keiichi Enomoto/AP/LLY@Lilly, Kenji Nobuhara/AP/LLY@Lilly, Koji Yamaguchi/AP/LLY@Lilly, Mayumi Hagiwara/AP/LLY@Lilly, Mikihiro Kosuge/AP/LLY@Lilly, Namie Hara/AP/LLY@Lilly, Rie Nagashiro/AP/LLY@Lilly, Sachiko Konaka/AP/LLY@Lilly, Takashi Taniguchi/AP/LLY@Lilly, Tetsu Kawade/AP/LLY@Lilly, Anna R Thornton/AP/LLY, James L Gahimer/AP/LLY, Jared G Kerr/AM/LLY, Michael L Zeckel/AM/LLY, Patrizia Cavazzoni/AM/LLY@Lilly, Yasuko Kojima/AP/LLY@Lilly, Yasushi Ito/AP/LLY@Lilly, Yukari Ohno/AP/LLY@Lilly, Yumi Kinoshita/AP/LLY@Lilly
::: Re: The result of the meeting with the MHLW today

ZY 8485 690

Akagi-san,

I understand that we have to distribute a letter to doctors.

Please explain to me how that will be organized - by mail or handed by MR's.

What do we have to write in this letter? Can we include results from studies and f. ex send the paper on data from the large prescription database in US?

Can we directly use the medical letter from global on hyperglycemia and diabetes?

Anne Bille

Noriko Akagi

Noriko Akagi

03/26/02 12:13 AM

To: Keiichi Enomoto/AP/LLY@Lilly, Yasushi Ito/AP/LLY@Lilly, Yumi Kinoshita/AP/LLY@Lilly, Yasuko Kojima/AP/LLY@Lilly, Sachiko Konaka/AP/LLY@Lilly, JP_Zyprexa_Safety, US_Zyprexa_Japan Safety List, Hiromasa Tara/AP/LLY@Lilly, Andrew J Wood/AP/LLY@Lilly
cc: Mayumi Hagiwara/AP/LLY@Lilly, Namie Hara/AP/LLY@Lilly, Tetsu Kawade/AP/LLY@Lilly, Mikihiro Kosuge/AP/LLY@Lilly, Rie Nagashiro/AP/LLY@Lilly, Kenji Nobuhara/AP/LLY@Lilly, Yukari Ohno/AP/LLY@Lilly, Fumiko Sakakibara/AP/LLY@Lilly, Takashi Taniguchi/AP/LLY@Lilly, Koji Yamaguchi/AP/LLY@Lilly

Subject: The result of the meeting with the MHLW today

Dear all

I would like to let you know the result of the meeting today.

From the beginning of the meeting, the officers strongly suggested we take safety actions, such as 'doctor letters' or the revision of 'contraindications' section in the JP package insert.

We, of course, did say we thought no safety actions were necessary now because of the following reasons:

- The JP package insert already mentions 'to pay attention to the treatment for the patients with diabetes risk factors', and 'diabetic coma and ketoacidosis'.
- Patients with schizophrenia have diabetes mellitus higher than the general population
- The incidence of diabetes between olanzapine v.s. haloperidol, or olanzapine v.s. risperidone were not different in studies.
- Incidences of diabetes are not different among antipsychotic agents
- According to a study, olanzapine does not effect insulin secretion
- Based on the result of the clinical trials, a 'doctor letter' or 'contraindications' are too strict.

The officers, however, said that they already know or understood what we have said. But the about 10 cases, especially including 2 death cases, for olanzapine have been reported in a only half years. Therefore, they called us to request some safety actions, including distribution of a 'Doctor letters' ASAP. If we do not take actions, they would strongly indicate safety actions, such as a 'doctor letters', or mentioning the patients with the risk factors in the 'contraindication' section. The officers also said that the actions taken by the authorities of EU or US are usually too late, so the MHLW would like to take the action appropriately.

So, we should make draft of the revision as soon as possible within a couple days and fax to the MHLW. Ito sennsei and I will talk with Wood-san tomorrow morning. We are planing that the draft will be made and sent to Indy tomorrow, and discussed at the tel conference in the evening of March 26 (Indy time) /morning of March 27 (Japan time) .

with best regards,
Noriko Akagi

ZY 8485 691



Jared G Kerr
03/25/2002 12:58 PM

To: Lisa A Vierhile/AM/LLY@Lilly
cc:
Subject: The result of the meeting with the MHLW today

FYI

----- Forwarded by Jared G Kerr/AM/LLY on 03/25/2002 12:57 PM -----

Noriko Akagi
03/25/2002 10:13 AM

To: Keiichi Enomoto/AP/LLY@Lilly, Yasushi Ito/AP/LLY@Lilly, Yumi Kinoshita/AP/LLY@Lilly, Yasuko Kojima/AP/LLY@Lilly, Sachiko Konaka/AP/LLY@Lilly, JP_Zyprexa_Safety, US_Zyprexa_Japan Safety List, Hiromasa Tara/AP/LLY@Lilly, Andrew J Wood/AP/LLY@Lilly
cc: Mayumi Hagiwara/AP/LLY@Lilly, Namie Hara/AP/LLY@Lilly, Tetsu Kawade/AP/LLY@Lilly, Mikihito Kosuge/AP/LLY@Lilly, Rie Nagashiro/AP/LLY@Lilly, Kenji Nobuhara/AP/LLY@Lilly, Yukari Ohno/AP/LLY@Lilly, Fumiko Sakakibara/AP/LLY@Lilly, Takashi Taniguchi/AP/LLY@Lilly, Koji Yamaguchi/AP/LLY@Lilly
Subject: The result of the meeting with the MHLW today

Dear all

I would like to let you know the result of the meeting today.

From the beginning of the meeting, the officers strongly suggested we take safety actions, such as 'doctor letters' or the revision of 'contraindications' section in the JP package insert.

We, of course, did say we thought no safety actions were necessary now because of the following reasons:

- The JP package insert already mentions 'to pay attention to the treatment for the patients with diabetes risk factors', and 'diabetic coma and ketoacidosis'.
- Patients with schizophrenia have diabetes mellitus higher than the general population
- The incidence of diabetes between olanzapine v.s. haloperidol, or olanzapine v.s. risperidone were not different in studies.
- Incidences of diabetes are not different among antipsychotic agents
- According to a study, olanzapine does not effect insulin secretion
- Based on the result of the clinical trials, a 'doctor letter' or 'contraindications' are too strict.

The officers, however, said that they already know or understood what we have said. But the about 10 cases, especially including 2 death cases, for olanzapine have been reported in a only half years. Therefore, they called us to request some safety actions, including distribution of a 'Doctor letters' ASAP. If we do not take actions, they would strongly indicate safety actions, such as a 'doctor letters', or mentioning the patients with the risk factors in the 'contraindication' section. The officers also said that the actions taken by the authorities of EU or US are usually too late, so the MHLW would like to take the action appriallytely.

So, we should make draft of the revision as soon as possible within a couple days and fax to the MHLW. Ito sennsei and I will talk with Wood-san tomorrow morning. We are planing that the draft will be made and sent to Indy tomorrow, and discussed at the tel conference in the evening of March 26 (Indy time) /morning of March 27 (Japan time) .

with best regards,
Noriko Akagi

ZY 8485 692

Printed by Lisa Vierhile



Jared G Kerr

03/25/2002 01:03 PM

To: Lisa A Vierhile/AM/LLY@Lilly

cc:

Subject: Japan Glucose

Lisa:

Here are the two reports sent to MHLW.



FINAL MHLW Response Global Data 22 March 200; FINAL Japan MHLW Response-Japan Cases 21 March 200

Let me know if you have any questions.

Sincerely,

Jared Kerr
Critical Issues-Customer Response Team
Zyprexa Product Team

O/F: (317)-433-7216/5101
jkerr@lilly.com

ZY 8485 693